A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. - Wikidata - wikimedia - TriplyDB

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

http://www.wikidata.org/entity/Q44795543

about

Aromatase Inhibitors for the adjuvant treatment of breast cancer in postmenopausal women Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Management of hot flashes in women with breast cancer Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens Clinical trial update: National Cancer Institute of Canada Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004 Early stopping of clinical trials Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions.Challenges in translating endpoints from trials to observational cohort studies in oncology Optimal management of hormone receptor positive metastatic breast cancer in 2016 Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance Lung cancer chemoprevention: current status and future prospects Breast cancer chemoprevention: progress and controversy.Breast cancer chemoprevention: old and new approaches Clinical utilities of aromatase inhibitors in breast cancer Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis Urinary lead exposure and breast cancer risk in a population-based case-control study.Estrogen receptor signaling in lung cancer The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer Cancer drug related cardiotoxicity during breast cancer treatment.Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.Adjuvant therapy use among Appalachian breast cancer survivors Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.Small optic cup sizes among women using tamoxifen: assessment with scanning laser ophthalmoscopy.Breast cancer (non-metastatic)Current strategies for the prevention of breast cancer Prevention, diagnosis and treatment of osteoporosis following menopause induced due to oncological disease.A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.Management of aromatase inhibitor-induced arthralgia.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines

P2860

Q24194371-450EFEB0-CC6F-4552-9486-431B80206D4C Q24605762-4DDE9BAA-A8F3-4F48-A48E-106E56ACF725 Q24633010-EBB0F607-0D92-4285-BF49-5E150AB12BDA Q24644229-36E190AA-DB62-4F10-BCA9-B221202340B6 Q24670339-A17C0AE9-DD6C-476B-989B-2090AD590B83 Q24796233-AD5CBEFF-651D-4DB2-97EE-E6637777AA42 Q24797524-E8750EA8-92F3-4A4C-971C-FD28661ACF79 Q24806223-7AE27A6D-14F2-401C-BE62-B35A91DB9054 Q24813532-0DE7B173-2BE5-4A5F-BAE2-DF0B86D705D8 Q25257621-B98CE84A-4544-485C-967E-E2114FC909D6 Q25257781-55899F04-E1F6-40CD-877B-FBC04FAA1344 Q26746190-DE32EA5B-D138-4655-99C0-78FD3A8DE0AE Q26777683-9934EEF0-9C98-43F6-A4E8-91E821B10E8E Q26782584-FE93A914-2626-45BB-950E-7EEE7A621A8E Q26795554-E20F9963-9CF6-4994-87E9-1021E1420BD5 Q26995495-ED4F85D1-26A6-485F-B98F-ACA5D40CD229 Q27692587-78FF21AF-C757-4EAF-8D2E-9A75A1CC0D81 Q27693259-395F1C1B-E25C-4B12-B7E5-6EABD7BBAD47 Q28081168-59C74DBD-F9F0-45D2-B631-BB8886406224 Q28087204-47C43E8B-E405-4060-B4F1-1A59831DC32F Q28387297-BA35C53A-146D-4FB4-8D64-E6A0197ACF4C Q28393484-A2F9D5A8-CF19-4DC7-B879-613FEB1C1BFF Q28397662-1023D90F-356B-454F-93C3-BDE9BD299F0E Q30251498-400717DB-57B6-4E08-B4CC-EA5C51769284 Q30275906-8BA3082A-611D-4C2E-A89F-416EAD392C2B Q30279083-0CD9ABB0-0737-48B4-B795-550D130874E1 Q30313653-EF402534-D360-4E37-B380-B9C039B94DAA Q30419888-563E8A77-EC8C-4F63-BAE8-89FC8D4D56D9 Q30438048-36C16E8E-0FDF-48FF-9101-47D5F3182B6E Q30860467-5AF4F847-E33C-46DA-9D09-3B8370F4F9B3 Q33239343-1BD19A27-DCCF-49AD-90AD-2950EE402188 Q33446778-974624C1-6FC8-4DA6-97EC-A980D7FD9E4A Q33599463-71F0E489-0724-4B39-B79D-51070FADE1C2 Q33610328-51E1C815-A46A-4B6A-B5FA-75103C4A8BC4 Q33618145-B45EC810-6D83-4E5F-AD21-C53AA2C14827 Q33631047-B21795F0-B21A-42E4-AFC6-1486E89D6D6B Q33676764-282899F2-6630-43FF-B7D3-B32B3BF0817B Q33680411-109D92D5-E95B-4DD1-B3F5-25982172EE44 Q33698446-43D4A11C-56AB-411F-9ADD-C95F2E6BB152 Q33718304-2B4AFDCE-3FA4-4D45-8639-3D646E3132C0

P2860

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

http://www.wikidata.org/entity/Q44795543

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

A randomized trial of exemesta ...... en with primary breast cancer.

@en

A randomized trial of exemesta ...... en with primary breast cancer.

@nl

type

label

A randomized trial of exemesta ...... en with primary breast cancer.

@en

A randomized trial of exemesta ...... en with primary breast cancer.

@nl

prefLabel

A randomized trial of exemesta ...... en with primary breast cancer.

@en

A randomized trial of exemesta ...... en with primary breast cancer.

@nl

P1433

Q44795543-320E4EAA-A7A2-485A-A034-438CF91D033D

P1476

Q44795543-11AE75AD-7AE4-4BB9-B129-0E78D31503F4

P2093

Q44795543-0087B03E-E668-4C70-BF0A-EE781511C80A

Q44795543-03A91EF8-8F1B-4676-8E58-48DC1157737B

Q44795543-113FD875-887C-4F4D-85B1-48E662D7976B

Q44795543-11DC8DE8-8E64-4F86-98B3-08BA3CB4518A

Q44795543-154AA731-ACFE-4B0E-A718-2DDE1D5873F1

Q44795543-1E224E62-D50F-416E-A039-6AAD750749D1

Q44795543-24A2CF17-449A-4326-A37B-E72E475CC99E

Q44795543-2BA8B482-6C1F-429F-A0C8-C015F371BB70

Q44795543-3C3561CA-2B5C-4541-9578-59284359580B

Q44795543-43CA59B5-3CC9-4DAE-A177-8051A6F2D06E

P304

Q44795543-EBAB5719-94C5-4377-BE6B-D062910405F6

P31

Q44795543-96BBE31E-B90F-4606-A0F5-ACE711FC9A2E

P356

Q44795543-7F78B7B1-4547-458B-BD4C-BD275D87125D

P407

Q44795543-782D93B8-70C8-40C1-8076-36F82D444F34

P433

Q44795543-A76D7F9D-7328-4E2A-BE06-1802424FD9F5

P478

Q44795543-D668BB87-3D81-4EF2-A9CD-7477E6680955

P50

Q44795543-13FF599D-63C9-4287-9C2C-15B4E46D49CF

Q44795543-16DB0115-3F1B-4C1F-BF5E-5E087D1A9AB5

Q44795543-290120B3-1C6F-4641-BA0F-C9D4A94C2207

Q44795543-946D1717-4332-4BA6-A874-730E64CA4077

Q44795543-DF049EC5-C24D-4576-8D65-E706A0AA58E5

P577

Q44795543-56D5D740-2454-4E79-A1CA-04E076BCCE44

P698

Q44795543-AE5CA3CC-8349-458D-90C6-01C789E878DE

P356

P1433

The New England Journal of Medicine

P1476

A randomized trial of exemesta ...... en with primary breast cancer.

@en

P2093

Alan S Coates

http://www.w3.org/2001/XMLSchema#string

Alan Stewart

http://www.w3.org/2001/XMLSchema#string

Claire F Snowdon

http://www.w3.org/2001/XMLSchema#string

Cornelius van de Velde

http://www.w3.org/2001/XMLSchema#string

David Dodwell

http://www.w3.org/2001/XMLSchema#string

Elizabeth Mickiewicz

http://www.w3.org/2001/XMLSchema#string

Emilio Bajetta

http://www.w3.org/2001/XMLSchema#string

Gianfilippo Bertelli

http://www.w3.org/2001/XMLSchema#string

Giorgio Cocconi

http://www.w3.org/2001/XMLSchema#string

Giorgio Massimini

http://www.w3.org/2001/XMLSchema#string

P304

1081-1092

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA040331

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

350

http://www.w3.org/2001/XMLSchema#string

P50

Per Eystein Lønning

Lesley Fallowfield

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15014181

http://www.w3.org/2001/XMLSchema#string